Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients.
Zhong L, Gan L, Wang B, Wu T, Yao F, Gong W, Peng H, Deng Z, Xiao G, Liu X, Na J, Xia D, Yu X, Zhang Z, Xiang B, Huo Y, Yan D, Dong Z, Fang F, Ma Y, Jin G, Su D, Liu X, Li Q, Liao H, Tang C, He J, Tang Z, Zhang S, Qiu B, Yang Z, Yang L, Chen Z, Zeng M, Feng R, Jiao J, Liao Y, Wang T, Wu L, Mi Z, Liu Z, Shi S, Zhang K, Shi W, Zhao Y.
Zhong L, et al. Among authors: wu t.
Cell. 2025 Jan 15:S0092-8674(24)01423-5. doi: 10.1016/j.cell.2024.12.010. Online ahead of print.
Cell. 2025.
PMID: 39826543